Chemosensitization by misonidazole in CCNU-treated spheroids and tumours. by Durand, R. E. & Chaplin, D. J.
Br. J. Cancer (1987), 56, 103-109
© The Macmillan Press Ltd.,
Chemosensitization by misonidazole in CCNU-treated spheroids and
tumours
R.E. Durand & D.J. Chaplin
Medical Biophysics Unit, B.C. Cancer Research Centre, 601 West 10th Avenue, Vancouver, B.C., Canada V5Z JL3
Summary Misonidazole has been demonstrated to enhance the cytotoxicity of several common antineoplastic
drugs in vitro and in vivo, and its mechanism of action as a chemosensitizer, though still unknown, is thought
to be dependent upon hypoxia. We have used fluorescence-activated cell sorting to evaluate
chemopotentiation by misonidazole as a function of cell position in V79 spheroids and KHT tumours. CCNU
toxicity was enhanced in all cell subpopulations of both tumours and spheroids, with greater consistency than
might be predicted on the basis of the known variations in oxygen tension. Further, both misonidazole and
CCNU as single agents were preferentially toxic in the less well oxygenated regions of each system, arguing
that differential toxicity canno t be implicated in the chemopotentiation observed. In fact, increased treatment
toxicity did not necessarily lead to increased chemopotentiation, nor was potentiation directly related to the
metabolism/binding of the misonidazole. Chemopotentiation in multicell systems thus appears to be a
complex, multi-factorial process.
Hypoxic cells develop spontaneously during the growth of
many solid tumours, and are known to be resistant to
ionizing radiation and implicated in resistance to several
antineoplastic drugs. Clearly, their presence in human
tumours may limit the effectiveness of cancer therapy.
Development of hypoxic cell radiosensitizers thus has a clear
rationale; the observations that many of these sensitizers
were preferentially toxic to hypoxic cells (Olive & McCalla
1975; Hall & Roizin-Towle 1975; Moore et al., 1976)
suggested that they may be complementary to many
conventional cancer chemotherapeutic agents, and could thus
be used effectively in combination treatments. Indeed, in a
number of instances an interaction between the sensitizer
and the chemotherapeutic agent was observed (Kelly et al.,
1979; Clement et al., 1980; Rose et al., 1980, and reviewed
by Siemann, 1984).
Many factors have been implicated in the phenomenon of
chemosensitization (see Brown 1982, and Siemann 1984 for
reviews), including differential toxicity (Kelly et al., 1979),
direct interactions between the sensitizer (or its toxic
metabolites, which are generally produced under hypoxic
conditions) and the chemotherapeutic agent itself (Taylor et
al., 1982), alterations of drug pharmacology or delivery
(Urtasun et al., 1982; Workman et al., 1983; Lee &
Workman 1986), inhibition of repair processes by chemo-
sensitizer treatment (Taylor et al., 1982; Mulcahy 1986), and
alterations of cellular drug sensitivity, by, for example, the
sensitizer selecting for surviving cells more vulnerable to the
chemotherapeutic agent due to cell cycle status or other
factors (Siemann, 1984). Perhaps the most consistent
observation, however, has been the apparent requirement of
hypoxia both in vitro (Brown, 1982; Mulcahy, 1984), and in
vivo (Siemann, 1984; Wheeler et al., 1984).
In this report, we present data evaluating the cytotoxic
effects of misonidazole, MISO, and N-(2-chloro-ethyl)-N'-
cyclohexyl-N-nitrosourea, CCNU, singly and in combination
against transplantable KHT tumours in C3H mice, and
Chinese hamster V79 spheroids in vitro. In both systems,
cells were selectively recovered from known positions
(Durand, 1982, 1983; Chaplin et al., 1985, 1986a, b) using
cell sorting techniques, permitting us to study drug
interactions in specific cell subpopulations of known
oxygenation status, and known radiosensitivities. Virtually
identical conclusions were forthcoming from the two
systems, despite the fact that they were utilized differently:
spheroids allow control of many external variables,
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permitting mechanistic studies, whereas murine tumours are
best used to address treatment efficacy in situ. Consequently,
spheroid cell response was assayed immediately following
drug exposure; tumours were excised for sorting some 18
hours after drug administration to avoid pharmacokinetic
problems (including complications of free drug during
tumour disaggregation), and to allow typical repair processes
to occur.
Additionally, with the spheroid system, we have used the
median-effect analysis described by Chou & Talalay (1984)
to quantify the type and degree of interaction between these
agents, thus permitting quantitative assessment of the
separable processes of enhanced toxicity, and chemo-
potentiation. Our results indicate that true potentiation
occurs, but in a manner largely independent of the ambient
oxygenation of the target cells.
Materials and methods
Tumour transplant and cell culture techniques
All animal experiments were performed using the KHT
sarcoma growing in 8-10 week old C3H mice. Tumours were
derived by subcutaneous transplantation of 105 viable cells
(prepared by enzymatic digestion) over the sacral region of
the back, and were used at diameters of 7-9mm. Chinese
hamster V79-171b lung cells were maintained as monolayers
with bi-weekly subcultivation in Eagle's minimal essential
medium (MEM) supplemented with 10% foetal bovine
serum (FCS); spheroids were grown in MEM plus 5% FCS
as previously described (Sutherland & Durand, 1976;
Durand, 1983). Spheroids were used at sizes in the range 0.6
to 0.8mm, and maintained in a conventional air/5% CO2
atmosphere until exposed to drugs or radiation.
Drugs and treatment
The clinical formulation of CCNU (CeeNu, Bristol
Laboratories of Canada, Candia, Quebec) was suspended in
peanut oil and injected at 0.25ml/25g mouse; in spheroids,
CCNU was dissolved in DMSO immediately before addition
to the normal growth medium. Misonidazole was supplied
by the USNCI (lot number ES 53881); 3H-misonidazole
(specific activity 527pCimg-1) was synthesised and
generously provided by Dr J. Raleigh of the Cross Cancer
Institute, Edmonton, and used in spheroids at a final
concentration of 10 ugml-1. For animal studies misonidazole
was dissolved in saline and injected at 0.5ml/25 g mouse,
simultaneously with CCNU. Spheroid cultures were changed
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to a 5% oxygen atmosphere immediately before initiating 2h
misonidazole exposures; CCNU was added for the last
30min of the sensitizer treatment.
Staining and cell sorting procedures
A Becton Dickinson dual laser FACS 440 was used for cell
sorting. For chemosensitization studies, Hoechst 33342
(purchased from Sigma) was prepared in saline and 10 Mg g -1
infused via the tail vein over a 30-45min period, 16-18 h
after MISO and CCNU administration, to provide a
representative picture of average tumour blood flow (Olive et
al., 1985; Chaplin et al., 1986b). For the radiation studies,
animals were infused with Hoechst 33342 (lO ggg-) during
the actual period of irradiation (Chaplin et al., 1986a).
Animals were killed by cervical dislocation 20min after
Hoechst infusion, and the tumour excised, washed with saline
(4°C), rapidly minced, and then incubated with an enzyme
cocktail of trypsin, DNase and collagenase for 30min at
37°C to produce single cells (Chaplin et al., 1986b). The soft
agar clonogenic assay was used for analysis of tumour cell
viability (Courtenay, 1976); plating efficiencies ranged from
0.41 to 0.60.
In spheroids, the Hoechst dye was added directly to the
drug-containing flask at 2 jiM for the final 20min of the drug
exposures (Durand, 1983; 1986). Excess drug and stain were
removed by aspiration, and after three washes, the spheroids
were reduced to a single cell suspension using 0.25% trypsin
at 37°C for 10-12min with continuous agitation.
Cell suspensions were maintained at 4°C during the
sorting procedures (always <1 h). The primary laser was
operated at 400mW and 488 nm with the UV laser at 40mW
in the 350-360 nm lines, and the Hoechst emission monitored
through a 449 + 10 nm band pass filter. Cells were recognized
by the forward scatter signal; the resulting signals from the
Hoechst stain and the 900 scatter signals were processed
through matched logarithmic amplifiers, and the ratio of
these signals used to generate a 'stain concentration' profile
which was integrated to define 10 windows of equal cell
numbers each (Durand, 1983). A stained but untreated
tumour or spheroid cell population was used to define the
plating efficiency of each sorted fraction; as in previous
studies (Durand, 1982, 1983; Chaplin et al., 1985, 1986a, b),
no systematic variation was observed.
Experiments to assess the toxicity of the Hoechst 33342
alone or in combination with misonidazole and CCNU were
negative insofar as no interactions were identified. However,
selective interactions in a subpopulation of cells cannot be
identified by measuring the entire population, yet
subpopulations cannot be studied without staining and
sorting. Thus, our controls were to use either drug alone, or
the combinations, at 2-3 levels of toxicity, and the stain
concentration was then escalated to determine the Hoechst
level at which additional cell killing occurred. At least 8-fold
higher Hoechst 33342 concentrations than those used for
sorting were required for any additional cell killing.
Median-effect analysis oJ interactions
As previously stated, we have adopted analytical procedures
(Chou & Talalay, 1984) based on the 'Median-Effect'
equation:
(I -S)/S = (D/Dm)m
where 'm' is the sigmoidicity of the curve, and 'Dm' the
median dose (which produces 50% survival). A log
transform of the equation simplifies solution for the
constants, and the dose giving survival S is then:
D =D.[(1-S)/S]1 /m.
Parallel curves for log(( -S)/S) vs log(D) for different drugs
indicate that the two agents can be added by dose, so if a
constant dose ratio is used, the fractional part of the effect
due to drug 1 (f1) varies with its concentration (Cl):
fl =Cl/(Cl +C2).
Thus, the 'Combination Index' (CI) can be defined at any
desired level of survival in terms of the calculated single
(D1,D2) or combined (D12) dosages needed to reach that
endpoint:
CI (DI2)(f1) (D12)(f2) (D12)(f1)(DI2)(f2)
DI D2 (D1)(D2)
where the last term is required only if the agents are non-
exclusive ('m' is greater for the combined treatment than for
either single agent). In essence, the combination index CI is
the ratio of the combination dose to the sum of the
(isoeffective) single-agent doses; consequently, CI< 1 shows
potentiation (synergism) where CI> I indicates antagonism
(protection).
Results
The KHT tumour system is sensitive to CCNU as a single
agent (Siemann, 1984), making it a good choice for chemo-
potentiation studies. Quite variable hypoxic fractions have,
however, been reported for this tumour (Moulder &
Rockwell, 1984). We find that tumours of the sizes used in
this study show a resolvable hypoxic fraction (10-20%),
though smaller than that which can be induced in the V79
spheroid system (55% in Figure 1) by incubation under a
5% oxygen atmosphere (simulating the highest oxygen
tension likely present in the tumour, and leading to marked
MISO/CCNU interactions in preliminary studies). Both
panels of Figure 1 show cellular radiosensitivity as a
function of Hoechst staining intensity; in spheroids, the
symmetry of the model allows an easy calculation of the
depth from which the cells were recovered (Durand, 1983),
while in the tumour system, the data are simply presented as
fraction number, where fraction I represented the 10% of
the cells which were most intensely stained (thus nearest the
functional blood supply, e.g. Chaplin et al., 1985,1986a).
Presenting the data in this way essentially describes the
'sensitivity profile' of cells to the treatment agent, where the
observed sensitivity is a function of cellular position relative
to the oxygen and nutrient supply (proximity to the medium,
in the case of the spheroids, or to blood vessels in the
tumour). Since radiosensitivity is known to be a critical
function of oxygenation, distributions like those shown in
Figure 1 thus indicate the oxygenation status of the various
cell subpopulations when irradiated. Use of the cell sorter
for plating precise numbers of cells leads to intra-experiment
reproducibility for spheroids approaching the size of the
plotted symbols (e.g., Durand, 1986, and subsequent
Figures).
The sensitivity profiles of spheroid or tumour cells to
CCNU as a single agent (Figure 2) indicated that the less
well oxygenated cells were more sensitive to this nitrosourea,
in agreement with previous results obtained with nitro-
soureas in other spheroid systems (Deen et al., 1980; Kwok
& Twentyman, 1985). Quite reproducible responses were
found in the multiple experiments shown (note that in the
case of spheroids, different starting sizes led to slightly
different estimates of cell depth among experiments).
Combinations of MISO and CCNU led to enhanced cell
killing in both systems (Figure 3), where the sensitivity
profile for each system to the single and combined agents
was compared to the expected response for 'independent'
effects of the MISO and CCNU. In both systems, more
killing was evident for the single and combined agents in the
hypoxic regions than in the more aerobic cells; additionally,
in both cases, more killing was observed than expected onMISO POTENTIATION OF CCNU TOXICITY 105
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Figure 1 Survival of cells recovered from irradiated V79 spheroids (panel a) or KHT tumours (panel b), expressed as a function
of depth in the spheroid, or proximity to the tumour blood supply. For reference, the expected responses under extremes of
oxygenation are indicated; the horizontal lines indicate the average response of the indicated population.
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Figure 2 Toxicity of CCNU to cells recovered from spheroids after a 30min exposure (panel a) or KHT tumours (panel b), and
expressed as in Figure 1. Note the similarity of tumour and spheroid response.
the basis of the independent toxicities of the two agents (the
light curves joining the dots show the product of the MISO
and CCNU toxicities). Thus, our data as presented in Figure
3 indicated that the agents produced more cytotoxicity than
was expected on the basis of independent toxicities, and
further, preferential toxicity was produced in the innermost,
more hypoxic regions. It is important to note, however, that
even cells from the well oxygenated regions of both the
tumours and spheroids showed enhanced toxicity when
treated with the combined modalities. Unfortunately, it is
not possible to deduce the type or magnitude of the
interaction between the agents from data presented in this
manner.
To dissociate cytotoxicity and interaction, a common
approach is to determine the sensitizer enhancement ratio, or
reduction in dose needed to achieve a desired endpoint. To
illustrate this for the experiments just shown, Figure 4
presents a compilation of data, where the left panel indicates
the net response to CCNU of cells recovered from near the
surface of spheroids, and the right panel, that of hypoxic
cells deeper within the spheroid. The stars are the
corresponding data points from those combination
treatments shown in Figure 3, displaced downward from the
predicted CCNU-only response by the 'excess' toxicity
remaining after correction for the expected MISO toxicity.
From this presentation, the combination treatment was
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Figure 3 Toxicity of misonidazole, CCNU, and the combination in spheroids and tumours. To achieve the comparable survival
levels shown, spheroids in 5% 02 were treated 30min with 3.2pgml-1 CCNU, and 2h with 3.2mgml-1 MISO; the tumour
exposures were 4.0mgkg-1 CCNU and 1.Omgg-1 MISO. The products of the independent toxicities of the two agents are also
shown.
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Figure 4 Toxicity of 30min CCNU treatments to oxic, external (panel a) or hypoxic, internal (panel b) cells of spheroids,
compiled from independent experiments (closed symbols are the data points also displayed in Figure 3). Additionally, the stars
indicate the MISO+CCNU survival levels measured in the experiments plotted in Figure 3, but normalized to indicate survival
relative to that expected for CCNU treatment alone (i.e., corrected for MISO toxicity). Isoeffective CCNU doses in the absence of
sensitizer averaged 1.19 higher for cells from Fraction 2, and 1.44 higher for the internal cells.
about as toxic as a 20% greater CCNU dose in the aerobic
fraction, and showed a further enhancement of only another
factor of 2 in the hypoxic cells. Similar analysis of the
tumour data results in less overall enhancement, and less
differential between oxic and hypoxic cell populations.
A better estimate of the interaction would, of course,
result from a more complete dose-response curve for the
combination treatments. However, this would provide
information at only one sensitizer concentration; we
consequently prefer the 'median effect' analysis proposed by
Chou and Talalay (1984) as a more general estimate of agent
interaction that is also more easily extended to different
exposure conditions.
The median effect equation allows a convenient
mathematical representation of survival data, with broad
applicability to most types of survival curves (Berenbaum,
1981; Chou & Talalay, 1984). The adequacy of the model
can be assessed by evaluating the goodness of fit of
'transformed' data as in Figure 5 for spheroids; this plot
essentially shows toxicity as a function of dose (each plotted
point represents the mean of 1-3 independent experiments;
unlike the previous figure, data are included for experiments
where 'paired' determinations of combination to single agent
toxicity were performed). Note that the representative data
(fraction 2, near the outer rim of the spheroids, and fraction
8 near the necrotic region) were nicely fit by the model, and
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Figure 5 Spheroid survival data from MISO (squares), CCNU
(circles), or combination treatments (triangles), transformed to
allow solution of the Median Effect equation. Only data for two
fractions (F2, open symbols, and F8, closed symbols) are shown;
the best-fit linear regression curves of each data set are also
indicated. Note the parallelism between the MISO and CCNU
data for each fraction, and the upward displacement of the
combination data, indicating that the response was potentiated.
the increased efficacy of each agent for the innermost cells
was reflected by the increased slopes of the fraction 8 curves.
The parallelism of the single agent curves (open and closed
squares, or circles) indicates the legitimacy of adding the
agent doses; the increased toxicity (upward displacement) of
the combined modality data (1000:1 MISO:CCNU by
weight) indicates a potentiated response.
The experimental data for all fractions through the
spheroids were equally amenable to this analysis. Thus, it
follows that a relatively simple interpolation between these
dose-response curves (if sort fraction rather than depth in
the spheroid is used in order to linearize the interpolation
increments) leads to analysis of MISO/CCNU interactions in
terms of the combination index, as in Figure 6. Note that in
this three-dimensional representation, the interaction
(combination index) between the agents is plotted on a
logarithmic scale as a function of both the level of effect and
of the position in the spheroid. The upper plane indicates an
independent response (no interaction); all combination index
values less than 1 indicate a synergistic interaction. As
before, sort fraction 1 indicates cells on the periphery of the
spheroid and fraction 10 is the 10% of the cells furthest
from the surface. From this representation one can
immediately appreciate that 'effective' doses of the two
agents can lead to potentiation, and further, that the
differential in interaction between the aerobic and hypoxic
(outer and inner) cells of the spheroid was highly dependent
upon the net treatment toxicity (i.e., the survival level). Like
Figure 4, this analysis suggests, however, that the internal,
hypoxic cells were only minimally more susceptible to
chemopotentiation for most exposure conditions.
To determine whether the observed interaction between
the agents was directly related to MISO metabolism and
binding, the radioactivity recovered in each cell fraction of
spheroids after addition of tracer levels of 3H-labelled
misonidazole was plotted similarly in Figure 7. Note that for
all fractions in the spheroids, MISO binding (incorporated
3H) was essentially a linear function of exposure concen-
tration. As was expected, the hypoxic regions of spheroids
bound more drug than the better oxygenated regions; this is
the basis of using misonidazole (Chapman et al., 1981) and
other nitroheterocycles (Olive & Durand, 1983) as probes for
hypoxic cells. If chemosensitization were directly correlated
to the binding of MISO, the spheroid chemosensitization
profile should be essentially the inverse of Figure 7 (which
Figure 6 clearly is not). Our preliminary observations on 3H-
MISO binding in tumours (unpublished), based on tumour
disaggregation and sorting, produced results quite similar to
the profiles shown for spheroids in Figure 7. Thus, the
enhanced toxicity of the combined CCNU and MISO in
tumours did not appear to correlate with MISO binding in
tumours to any greater degree than in spheroids.
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Figure 6 The 'Combination Index' for interaction of misonidazole and CCNU in V79 spheroids, plotted as a function of depth in
the spheroid (Sort Fraction 1 represents the outermost 10% of the cells), and survival level produced by the combination
treatment. For reference, the upper plane is drawn at the level of independent action (antagonistic interactions were truncated at
this level); increasing potentiation is indicated by decreasing values of the combination index. Note the constancy of the
interaction with respect to cell position, despite the known variation in oxygen tension through the spheroid.
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Figure 7 3H-misonidazole binding as a function of exposure concentration and position in the spheroid. Note that binding was
very linear with exposure for each fraction, but that maximal binding at higher MISO concentrations was not found in the
innermost cells of the V79 spheroids.
Discussion
The data reported here indicate that chemopotentiation of
CCNU toxicity by misonidazole occurred in all sub-
populations of spheroid cells, and greater than additive
cytotoxicity was observed in all cells of the KHT tumours.
Moreover, the observed potentiation occurred to a
surprisingly similar extent throughout each system, despite
the fact that some cells are equilibrated with a 5% oxygen
atmosphere, whereas others are at least orders of magnitude
lower in oxygen content, if not completely anoxic. Since
ploidy, cell cycle position, cycling rate, nutritional status,
and similar variables change substantially through these
subpopulations of cells, with little concomitant change in the
degree of sensitization seen, it seems safe to conclude that
these factors only minimally affect the net response.
In view of the somewhat different orientation of the
spheroid and tumour experiments, the similarity of the
conclusions reached with each system is gratifying. In
particular, it is unlikely that the Hoechst staining 18h after
drug treatment identifies and locates exactly the same cells
that were treated; the tumour is a dynamic system, with
active proliferation in the aerobic regions, and continuous
cell loss and replacement at greater distances from the
functional vasculature. Nonetheless, our sorting techniques
seem of particular value for hypoxia-targeted agents, since
cell turnover might result in some underestimate of toxicity
toward hypoxic cells, but would be expected to markedly
underestimate aerobic toxicity and/or interactions.
It is clear from thk conventional data presentation (Figure
3) that the observed cell kill from the combined treatments
was greater than that which was expected on the basis of
independent action of the two drugs. To go beyond that
general statement, and to determine whether more cyto-
toxicity necessarily indicates greater potentiation, requires a
more sophisticated analysis. The median effect analysis and
the derived combination index leads to a specific definition
of 'additivity', and identifies conditions under which the
agents are sub-additive (antagonistic) or supra-additive
(potentiating). Further, since the combination index is
essentially the dose ratio for iso-effective treatments, an
indication of the degree of interaction (as distinct from the
level of cytotoxicity) is immediately available from this type
of analysis.
Unfortunately, however, the median effect analysis also
has some problems. Close scrutiny of Figure 5, which is the
basis for the derived combination index, suggests that while
the median effect model fits quite well for the single agent
treatments, both combined modality treatments (triangles)
would be represented better by concave upward curves (on
the log-log plot). Forcing a linear curve through concave
upward data points underestimates the degree of interaction
at both low and high dose levels, and is thus quite sensitive
to the dose-range over which the data are obtained. At low
dose levels, this can produce apparent antagonism or, at
best, an overestimate of the degree of antagonism present
between the two agents. Conversely, at high doses, the
effectiveness of the agents and the degree of interaction is
underestimated. Both problems do, however, result in a
conservative estimate ofpotentiation.
Use of the cell sorter to select different subpopulations of
cells from the multicell systems, coupled with scintillation
counting of bound 3H-misonidazole in the sorted cells, leads
to the unique capability of correlating toxicity and drug
exposure. Comparison, however, of Figures 6 and 7 suggests
that the degree of interaction between MISO and CCNU (as
quantified by the combination index) does not appear to be
directly related to the sensitizer binding (and by inference, to
the cellular oxygenation status). An analogous lack of
correlation was observed when a nitrofuran, AF-2, was used
as the chemosensitizer in spheroids (Durand & Olive, 1986),
despite the fact that a good correlation was observed
between AF-2 uptake and toxicity (Olive & Durand, 1983;
Durand & Olive, 1986). It is important to note, however,
that maximal toxicity was observed in the most hypoxic cells
(Figure 3).
While the results reported here do not identify a 'specific'
mechanism of chemosensitization, they do argue against
'complementary toxicity' being an important factor; both
drugs show qualitatively similar toxicity profiles throughout
the two systems, preferentially killing the more hypoxic cell
populations in both. Thus, increasing the dosage of bothMISO POTENTIATION OF CCNU TOXICITY 109
agents might lead to 'wasted' activity, since the same cells
are preferentially killed by each, and the potential for
interactions would consequently be expected to decrease.
Other potential mechanisms of interaction include
enhancement of DNA damage, reduction of glutathione and
other endogenous protectors as a result of sensitizer
treatment, and inhibition of repair of CCNU-induced
damage. Again, one might expect that these mechanisms
should be fairly closely coupled to the intracellular MISO
concentrations, whereas the chemosensitization actually
observed was clearly not (comparing Figures 6 and 7). Our
data in the tumour system, showing enhanced CCNU
toxicity in MISO-treated animals is, however, consistent with
the expected result from MISO-induced elongation of the
CCNU exposure time in animals (Workman et al., 1983; Lee
& Workman, 1986); the fact that the spheroid data so closely
parallel the in vivo results argues that pharmacokinetic
alteration seems unlikely to be the only mechanism operative
in vivo. Thus, chemopotentiation is complex, and most likely,
multifactorial.
In conclusion, we believe that our data indicate the need
to perform chemosensitization experiments under highly
quantitative conditions. Further, they suggest that the
chemosensitization process is controlled or influenced by
multiple factors, which will have to be carefully balanced in
order to achieve optimum effects. Although the interaction
between MISO and CCNU is clearly not dependent upon
complementary toxicity, it would nonetheless seem
advantageous if a chemotherapeutic agent which showed
preferential toxicity to aerobic cells could in fact be chemo-
sensitized; our preliminary data using misonidazole and
melphalan (unpublished) suggest that both conditions can be
achieved. As chemopotentiation may have considerable
clinical potential, further studies addressing both mechanistic
questions and improved drug combinations seem warranted.
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